Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

AnGes stock

4563.T
JP3127700007
779518

Price

56.48
Today +/-
+0.01
Today %
+2.65 %

AnGes stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the AnGes stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the AnGes stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the AnGes stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze AnGes's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

AnGes Stock Price History

DateAnGes Price
12/5/202456.48 undefined
12/4/202455.00 undefined
12/3/202456.00 undefined
12/2/202457.00 undefined
11/29/202457.00 undefined
11/28/202456.00 undefined
11/27/202459.00 undefined
11/26/202461.00 undefined
11/25/202458.00 undefined
11/22/202455.00 undefined
11/21/202453.00 undefined
11/20/202452.00 undefined
11/19/202452.00 undefined
11/18/202449.00 undefined
11/15/202450.00 undefined
11/14/202451.00 undefined
11/13/202451.00 undefined
11/12/202449.00 undefined
11/11/202449.00 undefined
11/8/202448.00 undefined
11/7/202450.00 undefined
11/6/202450.00 undefined

AnGes Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into AnGes, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by AnGes from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects AnGes’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of AnGes. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into AnGes’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing AnGes’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on AnGes’s growth potential.

AnGes Revenue, EBIT and net profit per share

DateAnGes RevenueAnGes EBITAnGes Net Income
2023152.99 M undefined-11.97 B undefined-7.44 B undefined
202267.06 M undefined-16.31 B undefined-14.71 B undefined
202164.15 M undefined-15.63 B undefined-13.68 B undefined
202040 M undefined-5.6 B undefined-4.21 B undefined
2019326.76 M undefined-3.27 B undefined-3.75 B undefined
2018610.05 M undefined-3.07 B undefined-3 B undefined
2017365.18 M undefined-3.29 B undefined-3.76 B undefined
2016514.27 M undefined-4.76 B undefined-4.78 B undefined
2015430.15 M undefined-4.17 B undefined-4.14 B undefined
2014909.9 M undefined-2.27 B undefined-2.37 B undefined
2013491.3 M undefined-1.36 B undefined-1.41 B undefined
2012444.5 M undefined-1.79 B undefined-1.71 B undefined
2011243.4 M undefined-2.1 B undefined-1.82 B undefined
2010286.9 M undefined-2.01 B undefined-1.97 B undefined
2009585.7 M undefined-2.61 B undefined-2.92 B undefined
2008951.1 M undefined-2.76 B undefined-3.53 B undefined
20071.72 B undefined-2.04 B undefined-1.73 B undefined
20062.91 B undefined-1.52 B undefined-1.11 B undefined
20052.43 B undefined-1.97 B undefined-1.91 B undefined
20042.7 B undefined-1.56 B undefined-1.54 B undefined

AnGes Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.051.31.792.452.72.432.911.720.950.590.290.240.440.490.910.430.510.370.610.330.040.060.070.15
-2,788.8938.0036.739.91-9.8719.84-40.93-44.71-38.49-51.11-15.0382.7210.5985.13-52.7019.53-28.9967.12-46.56-88.0464.104.69126.87
42.221.461.060.770.700.780.65100.0094.7488.3871.3366.6770.9573.3283.3958.1465.9551.2369.0273.3141.0310.94-38.8112.50
00000001.720.90.520.20.160.320.360.760.250.340.190.420.240.020.01-0.030.02
0142-560-978-1,541-1,905-1,114-1,728-3,534-2,921-1,967-1,815-1,708-1,409-2,369-4,143-4,776-3,764-2,996-3,750-4,209-13,675-14,714-7,437
---494.3774.6457.5723.62-41.5255.12104.51-17.35-32.66-7.73-5.90-17.5168.1374.8815.28-21.19-20.4025.1712.24224.907.60-49.46
19.319.319.820.422.623.524.326.927.727.827.828.729.835.438.155.663.4476.2486.96104.73119.15147.27156.05189.28
------------------------
Details

Keystats

Revenue and Growth

The AnGes Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the AnGes is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (B)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                               
0.011.33.838.8786.184.789.987.35.053.051.580.362.36.022.0711.155.7810.0411.5417.911.044.16
023815885821421299975657876104109659132.69298.32142.69257.483.0612.710.269.8926.53
01112000000000000126.66166.0892.2173.04106.35280.31419.88392.080
00.160.80.530.550.440.440.570.590.520.640.610.650.620.360.671.171.571.010.641.191.221.011.57
0.010.040.51.110.861.10.850.820.350.310.380.370.230.280.561.240.990.480.420.21.151.870.450.17
0.011.755.310.69.497.866.211.478.315.944.142.641.343.317.594.243.623.437.5410.9914.1721.4312.95.92
00.160.20.20.220.210.150.110.10.060.070.060.050.020.030.080.0800.050.050.240.191.410.42
000000.421.231.070.860.830.520.950.680.430.440.320.720.470.41.421.080.880.920.36
00000000000000000000003920
02686106236376347307281212157142103705451.2155.160000000
0000.020.010.010.010.0800000000000022.7122.6823.2521.75
12304652521411311371301241119989747067.2968.1858.9460.0164.32162.74281.83337.29446.51
0.020.220.340.380.521.151.861.711.371.230.861.250.920.60.590.510.920.530.511.5324.1924.0326.3222.97
0.031.975.6310.9710.019.028.0613.189.687.165.013.892.263.918.184.754.543.968.0512.5238.3545.4639.2128.89
                                               
0.030.71.84.785.165.55.699.449.469.469.479.659.8511.5514.8515.2117.655.669.413.2924.6133.3635.1535.05
00.673.16.086.453.8247.757.777.777.787.968.169.8613.1613.5315.961.475.219.1122.7615.6817.473.42
-3139-421-1,399-2,941-1,859-2,973-4,684-8,176-11,057-12,978-14,748-16,492-17,887-20,318-24,519.52-29,338.42-3,434.57-6,627.04-10,341.58-14,501.5-12,346.14-27,049.26-18,290.37
00-0-0.01-0.01-00-0-0.03-0.03-0.05-0.05-0.04-00.030.030.010.0100-0.251.94.845.89
000-2-1033-225-46370684542591517-29.94-416.78-80.83-248.48-5.4159.1936.4419.424.76
0.031.514.489.458.667.466.7612.288.966.514.293.271.743.547.744.223.873.627.7312.0632.6838.6330.4326.1
0919610811711110010974998606742207246.56389.13201112.93183.01514.13720.71553.25426.45
1764045486161121221813723.3687.78.2316.4912.3768.9480.3690.09130.21
00.440.951.351.121.381.130.760.690.590.60.520.420.290.210.210.150.110.160.255.015.936.521.79
000000000000000000000000
0000000000000000000000160.74147.73
00.461.151.491.241.51.280.880.710.650.720.60.510.350.420.480.630.320.290.445.596.737.322.49
0000000000000000000000994.97214.95
0000002200000001026.416.261.271.72.339.3119.112.4216.83
000000000001715151522.3622.6522.922.8923.9145.7668.4864.3264.43
0000000.0200000.020.020.020.030.050.040.020.020.030.090.091.070.3
00.461.151.491.241.51.30.880.710.650.720.620.520.360.450.530.670.340.320.475.676.828.42.79
0.031.975.6310.959.98.968.0613.159.687.1653.892.263.98.184.754.543.968.0512.5238.3545.4638.8228.89
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of AnGes provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand AnGes's financial health and stability.

Assets

AnGes's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that AnGes must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of AnGes after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into AnGes's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0277-558-978-1,540-1,948-1,170-1,766-3,551-2,910-1,947-1,807-1,701-1,402-2,357-4,124-4,760-3,744-3,003-3,751-4,204-13,735-14,717-7,070
00.050.120.140.150.170.180.160.230.130.10.110.090.060.050.050.070.030.010.010.012.432.93.11
000000000000000000000000
0-0.15-0.340.11-0.020.060.05-0.450.360.07-0.16-0.08-0.03-0.18-0.51-0.57-0.32-00.510.962.560.171.8-5.36
0-55041-21364578985494159699631174529725-36608-1,323-237-1,200575
0190000000000000000012000
0013514151313111615965111526523-204284986
1165-731-689-1,433-1,686-898-1,976-1,978-2,225-1,842-1,705-1,631-1,456-2,703-4,599-4,983-2,991-2,522-2,179-2,961-11,380-11,214-8,745
-3-205-223-174-326-298-120-79-114-45-47-83-22-14-18-63-70-9-50-6-80-80-19-89
-0.02-0.22-0.24-4.482.96-0.34-0.7-3.671.53-0.530.950.770.01-0.03-0.05-0.07-0.830.23-0.12-1.25-6.96-0.15-0.1-0.36
-0.01-0.02-0.02-4.313.29-0.04-0.58-3.591.64-0.4910.850.03-0.01-0.03-0.01-0.760.24-0.07-1.24-6.88-0.07-0.08-0.27
000000000000000000000000
000000000000000000000000
0.021.343.55.930.740.690.387.450.030.010.010.370.393.376.450.724.772.837.227.6811.3317.283.522.03
0.021.343.515.930.90.690.47.450.030.010.010.370.393.396.430.724.792.927.287.6811.417.383.572.04
001101610190000-3015-22026846407297503
000000000000000000000000
01.292.530.742.43-1.32-1.21.8-0.48-2.75-0.9-0.58-1.221.943.72-3.94-1.070.154.644.261.56.3-6.87-6.88
-2.1-39.7-954.8-863.8-1,760-1,984.8-1,018.3-2,056.1-2,093-2,270.3-1,890.6-1,789.1-1,653.1-1,471.4-2,721.9-4,663.03-5,054.69-3,000.5-2,572.94-2,186.32-3,042.25-11,460.77-11,233.82-8,835.09
000000000000000000000000

AnGes stock margins

The AnGes margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AnGes. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AnGes.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the AnGes's sales revenue. A higher gross margin percentage indicates that the AnGes retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the AnGes's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the AnGes's total revenue generated. When comparing the revenue margin year over year, investors can gauge the AnGes's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the AnGes. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the AnGes's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

AnGes Margin History

AnGes Gross marginAnGes Profit marginAnGes EBIT marginAnGes Profit margin
202312.71 %-7,822.67 %-4,861.66 %
2022-40.01 %-24,320.76 %-21,942.37 %
202111.58 %-24,358.89 %-21,318.8 %
202042.45 %-13,999.18 %-10,524.3 %
201973.31 %-1,000.74 %-1,147.89 %
201869.15 %-502.46 %-491.21 %
201751.24 %-900.56 %-1,030.91 %
201666.07 %-926.24 %-928.85 %
201558.22 %-969.88 %-963.22 %
201483.4 %-249.91 %-260.38 %
201373.3 %-277.47 %-286.93 %
201270.93 %-401.66 %-384.34 %
201166.64 %-863.06 %-745.73 %
201071.14 %-700.7 %-685.67 %
200988.36 %-445.77 %-498.79 %
200894.82 %-289.81 %-371.61 %
2007100 %-118.58 %-100.49 %
200612.71 %-52.3 %-38.28 %
200512.71 %-81.09 %-78.39 %
200412.71 %-57.9 %-57.17 %

AnGes Stock Sales Revenue, EBIT, Earnings per Share

The AnGes earnings per share therefore indicates how much revenue AnGes has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue AnGes earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates AnGes's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of AnGes’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating AnGes's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

AnGes Revenue, EBIT and net profit per share

DateAnGes Sales per ShareAnGes EBIT per shareAnGes Earnings per Share
20230.81 undefined-63.23 undefined-39.29 undefined
20220.43 undefined-104.51 undefined-94.29 undefined
20210.44 undefined-106.1 undefined-92.86 undefined
20200.34 undefined-46.99 undefined-35.33 undefined
20193.12 undefined-31.22 undefined-35.81 undefined
20187.02 undefined-35.25 undefined-34.46 undefined
20174.79 undefined-43.14 undefined-49.38 undefined
20168.11 undefined-75.08 undefined-75.29 undefined
20157.74 undefined-75.04 undefined-74.53 undefined
201423.88 undefined-59.68 undefined-62.18 undefined
201313.88 undefined-38.51 undefined-39.82 undefined
201214.92 undefined-59.91 undefined-57.33 undefined
20118.48 undefined-73.2 undefined-63.24 undefined
201010.32 undefined-72.31 undefined-70.76 undefined
200921.07 undefined-93.92 undefined-105.09 undefined
200834.34 undefined-99.51 undefined-127.6 undefined
200763.94 undefined-75.83 undefined-64.26 undefined
2006119.84 undefined-62.68 undefined-45.88 undefined
2005103.43 undefined-83.87 undefined-81.07 undefined
2004119.31 undefined-69.08 undefined-68.21 undefined

AnGes business model

AnGes Inc is a Japanese biotechnology company specializing in the development and commercialization of therapies for cardiovascular, immunology, and oncology disorders. The company was founded in 1999 by experienced scientist Dr. Ryuichi Morishita. AnGes' technology is based on the use of DNA plasmids to deliver genes into human cells. This method offers a high level of control and precision in modifying genetic material, with the potential to revolutionize biotherapy. The company has conducted several successful clinical studies and acquired multiple patents related to their technology. Overall, AnGes operates in three main areas: cardiovascular medicine, oncology, and immunology. The company distributes a range of products and solutions for these fields, including therapies for heart failure, angina, cancer, and autoimmune diseases. AnGes' most well-known product currently is Collategene, used for the treatment of angina. Collategene is a therapy consisting of a combination of DNA plasmids and a special gel injected into the arteries. The gel promotes the formation of new blood vessels, supplying oxygen and nutrients to damaged tissue, supporting the repair and regeneration of the heart muscle. Another important product from AnGes is HGFgene, used to treat heart failure and chronic wounds. HGFgene contains essential growth factors that stimulate the formation of new blood vessels and tissue regeneration, potentially improving heart function. In addition to these products, AnGes also offers solutions for oncology, including a therapy called Protransgene used for pancreatic cancer treatment. Protransgene contains specific DNA plasmids that produce tumor-specific antigens and stimulate the body's immune system to fight the tumor. In immunology, AnGes has developed a technology called NFkB-decoy, with the potential to treat various inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. NFkB-decoy consists of synthetic DNA plasmids introduced into inflammatory cells, with anti-inflammatory effects. Overall, AnGes Inc. has established itself as a leading provider of biotherapeutics in Japan and is currently expanding into the US market. The company has an impressive track record in clinical research and development of innovative therapy options with the potential to improve the lives of millions of people. AnGes is one of the most popular companies on Eulerpool.com.

AnGes SWOT Analysis

Strengths

AnGes Inc has a strong and experienced management team.

The company has a strong portfolio of intellectual property and patents.

AnGes Inc has a well-established brand reputation in the industry.

Weaknesses

AnGes Inc has a limited product line and is heavily dependent on a few key products.

The company has a small market share compared to its competitors.

AnGes Inc faces challenges in terms of scalability and expanding into new markets.

Opportunities

There is a growing demand for the company's products in the healthcare industry.

AnGes Inc can explore partnerships and collaborations to expand its reach.

The company can invest in research and development to develop new innovative products.

Threats

Increasing competition from other companies in the market poses a threat to AnGes Inc.

Regulatory changes and strict compliance requirements can impact the company's operations.

Fluctuating market conditions and economic factors can affect the overall demand for AnGes Inc's products.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

AnGes Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

AnGes historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

AnGes shares outstanding

The number of shares was AnGes in 2023 — This indicates how many shares 189.277 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue AnGes earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates AnGes's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of AnGes’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating AnGes's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

AnGes stock splits

In AnGes's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for AnGes.

AnGes shareholders

%
Name
Stocks
Change
Date
1.84448 % Morgan Stanley & Co. International Plc3,713,0452,884,8456/30/2024
0.70043 % Hayashi (Yuichiro)1,410,00050,0006/30/2024
0.68875 % Kawai (Yutaka)1,386,500296,7006/30/2024
0.60649 % Simplex Asset Management Co., Ltd.1,220,9001009/30/2024
0.58955 % Shionogi & Co Ltd1,186,80006/30/2024
0.53809 % Toyooka (Yukiharu)1,083,2001,083,2006/30/2024
0.36323 % Nomura Securities Co., Ltd.731,200-91,1236/30/2024
0.35990 % Fujita (Kyoko)724,50070,0006/30/2024
0.35697 % Daiwa Securities Co., Ltd.718,600-35,3006/30/2024
0.34773 % Otsuki (Toshimi)700,00050,0006/30/2024
1
2
3

AnGes Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
SupplierCustomer0,520,380,68-0,07-0,18-0,62
SupplierCustomer0,460,510,250,28-0,85-0,82
SupplierCustomer0,26-0,18-0,360,18-0,69-0,61
SupplierCustomer0,040,07-0,76-0,610,690,38
SupplierCustomer-0,02-0,28-0,340,290,780,64
SupplierCustomer-0,05-0,44 0,150,66-0,67
SupplierCustomer-0,200,05-0,51-0,150,21-0,54
SupplierCustomer-0,27-0,47-0,280,250,950,05
SupplierCustomer-0,45-0,320,060,250,980,72
1

Most common questions regarding AnGes

What values and corporate philosophy does AnGes represent?

AnGes Inc represents values of innovation, integrity, and commitment to improving human health. The company's corporate philosophy revolves around pioneering advanced technologies and providing cutting-edge solutions for medical needs. AnGes is dedicated to developing and commercializing innovative gene therapy products that address significant unmet medical needs. With their in-depth expertise and research-driven approach, AnGes strives to create breakthrough therapies that positively impact patient lives. By consistently pushing the boundaries of science and focusing on high-quality development processes, AnGes Inc aims to revolutionize the healthcare industry, making a profound difference in the treatment of various diseases.

In which countries and regions is AnGes primarily present?

AnGes Inc is primarily present in Japan and other Asian countries such as China and South Korea. With its headquarters in Osaka, Japan, AnGes Inc has established a strong presence in the pharmaceutical industry within the region. This Japanese company specializes in the research and development of innovative gene therapy products and has expanded its operations to include clinical trials and collaborations with various medical institutions. AnGes Inc's focus on these countries and regions reflects its commitment to advancing healthcare solutions and improving patient outcomes in Asia and beyond.

What significant milestones has the company AnGes achieved?

AnGes Inc has achieved significant milestones throughout the years. Notably, the company successfully developed and obtained approval for the world's first gene therapy product, HGF plasmid, for critical limb ischemia. Additionally, AnGes Inc achieved remarkable results in clinical trials for its novel COVID-19 DNA vaccine, which showcased promising immunogenicity and safety profiles. Moreover, the company has consistently focused on advancements in DNA medicine technology, further expanding its portfolio with innovative therapeutic candidates. With their groundbreaking research and pioneering gene therapy products, AnGes Inc continues to lead the way in the field of biotechnology and revolutionize the treatment landscape.

What is the history and background of the company AnGes?

AnGes Inc. is a Japanese biopharmaceutical company that specializes in the development and commercialization of genetic medicines. Founded in 1999, the company has a rich history of research and innovation in the field of DNA-based therapies. AnGes Inc. has been actively involved in the development of innovative gene therapies for treating various diseases, including cardiovascular disorders and muscular dystrophy. With its cutting-edge technology and expertise, the company has established itself as a leading player in the genetic medicine industry. AnGes Inc. continues to strive for advancements in medical science through its dedication to research and development, aiming to improve the quality of life for patients worldwide.

Who are the main competitors of AnGes in the market?

The main competitors of AnGes Inc in the market include companies such as Novartis AG, Pfizer Inc, Moderna Inc, BioNTech SE, and Johnson & Johnson.

In which industries is AnGes primarily active?

AnGes Inc primarily operates in the pharmaceutical and biotechnology industries.

What is the business model of AnGes?

The business model of AnGes Inc revolves around biotechnology and pharmaceutical research. AnGes focuses on developing innovative therapeutic solutions for various diseases, including cardiovascular, ophthalmic, and infectious diseases. The company specializes in gene therapy and has a strong emphasis on utilizing its proprietary technology called "Non-viral Gene Transfer" to deliver therapeutic genes to target cells in the human body. By harnessing the potential of gene therapy, AnGes aims to provide effective treatments that can significantly improve patients' quality of life. AnGes Inc continues to invest in research and development to advance its product pipeline and further contribute to the healthcare industry.

What is the P/E ratio of AnGes 2024?

The P/E ratio cannot be calculated for AnGes at the moment.

What is the P/S ratio of AnGes 2024?

The P/S cannot be calculated for AnGes currently.

What is the Quality Investing of AnGes?

The Quality Investing for AnGes is 5/10.

What is the revenue of AnGes 2024?

The revenue cannot currently be calculated for AnGes.

How high is the profit of AnGes 2024?

The profit cannot currently be calculated for AnGes.

What is the business model of AnGes

AnGes Inc is an innovative Japanese biotechnology company specializing in the development of new therapies for serious diseases. The company was founded in 1999 and is headquartered in Osaka, Japan. AnGes is known for its groundbreaking approaches to the development of gene therapies based on DNA plasmids to treat genetic diseases. AnGes has divided itself into three main business areas, namely Therapeutics, Diagnostics, and Research, to provide a comprehensive range of products. In the Therapeutics area, they focus on the development and marketing of gene therapies for the treatment of cardiovascular diseases, eye diseases, and cancer. Here, AnGes has developed its flagship product called Collategene, which is used to treat peripheral artery occlusive disease (PAOD). Collategene is a gene therapy that continuously promotes the formation of new blood vessels, contributing to the restoration of blood supply. In the Diagnostics area, AnGes offers a wide range of test kits and analysis tools to support diagnoses for various diseases. These include tests for markers of infectious diseases such as dengue and Zika viruses, as well as tests for cancer diagnosis. Through collaboration with leading in vitro diagnostics manufacturers and laboratories, AnGes supports the development of new and improved diagnostic tests. In the Research area, AnGes offers support and consultation for the development of gene therapies and drugs for customers from various industries. AnGes provides customized solutions for a wide range of applications, from the pharmaceutical industry to agriculture and biotech companies. Here, AnGes utilizes its proprietary DNA technology for the development of new drugs and promotes collaboration between industry and academic institutions. AnGes' business model is based on its promising gene therapy technology, which allows for targeted injection of DNA plasmids into damaged tissue, promoting the formation of new blood vessels and the regeneration of damaged tissue. This can provide compelling benefits for patients suffering from serious diseases such as PAOD and cancer. AnGes has established partnerships with leading pharmaceutical and biotech companies such as Mitsubishi Chemical, Sumitomo Chemical, and Shionogi to support the development and marketing of its products. These partnerships strengthen AnGes' product offering and expand its geographical portfolio in Asian and European markets. In summary, AnGes Inc is a company specialized in gene therapy that offers a comprehensive range of products for the treatment of various diseases. The company is on a growth trajectory and aims to improve the health and well-being of patients worldwide by providing innovative therapies. Through its dedicated research activities and collaboration with industry and academic institutions, AnGes strives to expand its expertise in gene therapy and develop new and improved solutions for patients.

What is the AnGes dividend?

AnGes pays a dividend of 0 JPY distributed over payouts per year.

How often does AnGes pay dividends?

The dividend cannot currently be calculated for AnGes or the company does not pay out a dividend.

What is the AnGes ISIN?

The ISIN of AnGes is JP3127700007.

What is the AnGes WKN?

The WKN of AnGes is 779518.

What is the AnGes ticker?

The ticker of AnGes is 4563.T.

How much dividend does AnGes pay?

Over the past 12 months, AnGes paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AnGes is expected to pay a dividend of 0 JPY.

What is the dividend yield of AnGes?

The current dividend yield of AnGes is .

When does AnGes pay dividends?

AnGes pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of AnGes?

AnGes paid dividends every year for the past 0 years.

What is the dividend of AnGes?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is AnGes located?

AnGes is assigned to the 'Health' sector.

Wann musste ich die Aktien von AnGes kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of AnGes from 12/5/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 12/5/2024.

When did AnGes pay the last dividend?

The last dividend was paid out on 12/5/2024.

What was the dividend of AnGes in the year 2023?

In the year 2023, AnGes distributed 0 JPY as dividends.

In which currency does AnGes pay out the dividend?

The dividends of AnGes are distributed in JPY.

All fundamentals about AnGes

Our stock analysis for AnGes Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AnGes Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.